Brief: Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection
05/02/2025 17:22
Feb 5 (Reuters) - Shanghai Henlius Biotech Inc
2696.HK :
* EUROPEAN COMMISSION APPROVED SERPLULIMAB INJECTION IN
COMBINATION WITH CHEMOTHERAPY
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln